AMSTERDAM, Oct. 1, 2026 /PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA), a pioneer in treatments for rare IgG related immunologic conditions, today announced a partnership with Cradle, which builds the leading AI-driven protein design and engineering platform for biologics. Hansa will use Cradle's end-to-end platform across its discovery pipeline to design, optimize, and advance novel therapeutic candidates. Leveraging Cradle's AI driven protein engineering platform, the companies aim to accelerate the development of new therapeutics for patients with severe autoimmune diseases.

Hansa's lead product, imlifidase, is a first-in-class enzyme which is commercially available in Europe under the brand name Idefirix and is presently in FDA review with a PDUFA date in December for highly sensitized patients awaiting kidney transplant.

"We evaluated several AI models and vendors and selected Cradle because it combines three capabilities we believe are essential for next-generation protein engineering: end-to-end support across the discovery pipeline, from hit identification onward; multi-parameter optimization across complex engineering objectives; and active learning from our own data to drive increasingly predictable outcomes. Each accelerates our lab-in-the-loop process. Cradle's platform enables Hansa scientists to design and engineer better therapeutic candidates, faster and with greater probability of success," said Sofia Järnum, VP Head of Research and Early Development at Hansa.

The collaboration reflects Hansa's continued strategic investment in AI-powered drug discovery as it builds the next generation of its pipeline. Cradle's track record of delivering results with leading biopharmaceutical companies made it a natural partner as Hansa expands its use of AI across new discovery programs. The partnership reflects a growing shift toward unified AI platforms that combine candidate generation, optimization, and continuous learning from experimental data in a single workflow. According to Cradle, customers report development timelines up to 18 months faster, suggesting translation into significant R&D savings per clinical candidate.

"The future of multimodality therapeutics engineering isn't about spending more AI tokens or navigating a stable of models. It's about empowering scientists with a platform that learns alongside them, while enabling them to apply their unique human expertise to solve complex molecular challenges at scale, with speed and precision," said Stef van Grieken, CEO and Co-Founder of Cradle. "We're excited to partner with Hansa on their mission to accelerate the discovery and development of novel, high quality therapeutics for patients suffering from rare and severe autoimmune disorders."

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com  and follow us on LinkedIn.

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

About Cradle

Cradle's mission is to enable every scientist to turn today's impossible cures, foods, and materials into tomorrow's ordinary. Cradle's end-to-end protein engineering platform helps scientists intentionally engineer biologics across the full design-to-candidate lifecycle, bringing AI-driven molecular engineering, active learning from experimental data, and multi-property optimization together in a single system. Today, the platform is trusted by many of the biggest names in global pharmaceutical, industrial bio, agriculture and consumer goods across more than 80 active R&D programs. Cradle is based in Amsterdam, The Netherlands; Zürich, Switzerland and the United States with a team of machine learning and biotech research experts with deep industry experience from many of the world's leading technology and biotech companies. Cradle is backed by IVP as well as Index Ventures and Kindred Capital. For more information, visit cradle.bio.

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-partners-with-cradle-to-advance-ai-driven-protein-design-and-engineering-302895909.html

Sandro Brotz kehrt dem Schweizer Radio und Fernsehen den Rücken und wechselt Anfang 2027 zur Boulevardzeitung «Blick». Der 56-jährige Journalist, derzeit Moderator und stellvertretender Leiter der Polit-Talksendung «Arena», wird SRF Ende Januar 2027 verlassen. Bis voraussichtlich Mitte Januar führt er weiterhin durch die «Arena». Beim zum Ringier-Konzern gehörenden «Blick» soll Brotz einen neuen Video-Podcast aufbauen und moderieren, der mehrmals pro Woche Themen aus Politik, Wirtschaft und Gesellschaft aufgreift.

Der Schritt markiert das Ende einer knapp 15-jährigen SRF-Ära für Brotz. Seit seinem Wechsel nach Leutschenbach im Juni 2012 prägte er zunächst als Moderator der investigativen Sendung «Rundschau» das Programm, später zusätzlich als Gastgeber des «Rundschau Talk». 2019 übernahm er schliesslich die «Arena» von Jonas Projer. Als Grund für den Wechsel nennt Brotz die Möglichkeit, bei «Blick» ein neues Format mitzuentwickeln und damit über die Rolle des klassischen Moderators hinauszugehen. Ganz neu ist das Ringier-Umfeld für ihn nicht: Vor seiner SRF-Zeit war er bereits unter anderem stellvertretender Chefredaktor des «SonntagsBlick».

Der Abgang von Brotz wirft bei SRF unmittelbar die Nachfolgefrage auf. Als Topfavorit galt zuletzt sein Kollege Mario Grossniklaus, der seit 2024 einmal im Monat die «Arena» moderiert und damit Brotz entlastet. Der 49-Jährige hat dieser Spekulation nun jedoch eine klare Absage erteilt. Auf Linkedin schrieb Grossniklaus, er werde sich nicht auf die Nachfolge seines «geschätzten Kollegen» bewerben. Stattdessen wolle er sich auf seine Aufgaben in der Wahlleitung von SRG und SRF konzentrieren – eine Funktion, die er als «grösste und spannendste Aufgabe» seiner bisherigen Karriere bezeichnet.

Mit der Absage von Grossniklaus bleibt offen, wer Brotz ab etwa Mitte Januar beerben wird. SRF verweist darauf, man wolle sich vorerst auf eine geordnete Übergabe der «Arena» konzentrieren. Der Wechsel von Brotz reiht sich ein in eine Serie prominenter Abgänge von SRF in Richtung Dufourstrasse: Bereits zuvor hatten unter anderem Reto Scherrer, Steffi Buchli, Christine Maier, Hannes Britschgi und der frühere «Arena»-Moderator Jonas Projer den Schritt zum Ringier-Konzern gewagt. Die Motive reichen von besseren Angeboten bis hin zum Wunsch, den eigenen Namen in neuen Rollen und Formaten zu positionieren – mit sehr unterschiedlichem Ausgang.